BR0209986A - Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias - Google Patents

Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias

Info

Publication number
BR0209986A
BR0209986A BR0209986-1A BR0209986A BR0209986A BR 0209986 A BR0209986 A BR 0209986A BR 0209986 A BR0209986 A BR 0209986A BR 0209986 A BR0209986 A BR 0209986A
Authority
BR
Brazil
Prior art keywords
treatment
combination
agonist
anticholinergic agent
obstructive airway
Prior art date
Application number
BR0209986-1A
Other languages
English (en)
Inventor
Roisin A Armstrong
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0209986A publication Critical patent/BR0209986A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"AGONISTA DE A2A EM COMBINAçãO COM UM AGENTE ANTICOLINéRGICO, PARA O TRATAMENTO DE DOENçAS OBSTRUTIVAS DAS VIAS RESPIRATóRIAS". A presente invenção refere-se a uma combinação de um agonista do receptor A~ 2a~ de adenosina seletivo e um agente anticolinérgico para administração simultânea, seq³encial ou separada pela via inalada no tratamento de uma doença obstrutiva das vias respiratórias ou outra doença inflamatória, com a condição de que o agente anticolinérgico nao seja um sal de tiotrópio.
BR0209986-1A 2001-05-25 2002-05-24 Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias BR0209986A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition
PCT/EP2002/005725 WO2002096462A1 (en) 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Publications (1)

Publication Number Publication Date
BR0209986A true BR0209986A (pt) 2004-04-06

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209986-1A BR0209986A (pt) 2001-05-25 2002-05-24 Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias

Country Status (22)

Country Link
US (1) US20040171576A1 (pt)
EP (1) EP1395287A1 (pt)
KR (1) KR20030097901A (pt)
CN (1) CN1535161A (pt)
AP (1) AP2003002911A0 (pt)
BG (1) BG108383A (pt)
BR (1) BR0209986A (pt)
CA (1) CA2448086A1 (pt)
CO (1) CO5540324A2 (pt)
CZ (1) CZ20033126A3 (pt)
EE (1) EE200300586A (pt)
HU (1) HUP0400029A2 (pt)
IL (1) IL158774A0 (pt)
MA (1) MA27028A1 (pt)
MX (1) MXPA03010787A (pt)
NO (1) NO20035202D0 (pt)
OA (1) OA12609A (pt)
PA (1) PA8546101A1 (pt)
PL (1) PL366899A1 (pt)
SK (1) SK14302003A3 (pt)
SV (1) SV2003001055A (pt)
WO (1) WO2002096462A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
NZ556354A (en) 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
AP2003002911A0 (en) 2003-12-31
EP1395287A1 (en) 2004-03-10
MA27028A1 (fr) 2004-12-20
PL366899A1 (en) 2005-02-07
CA2448086A1 (en) 2002-12-05
EE200300586A (et) 2004-04-15
SV2003001055A (es) 2003-11-14
MXPA03010787A (es) 2004-03-02
CN1535161A (zh) 2004-10-06
OA12609A (en) 2006-06-09
IL158774A0 (en) 2004-05-12
PA8546101A1 (es) 2003-12-10
BG108383A (bg) 2004-08-31
US20040171576A1 (en) 2004-09-02
NO20035202D0 (no) 2003-11-24
CO5540324A2 (es) 2005-07-29
HUP0400029A2 (hu) 2004-04-28
SK14302003A3 (sk) 2004-08-03
KR20030097901A (ko) 2003-12-31
CZ20033126A3 (cs) 2004-09-15
WO2002096462A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
BR0209986A (pt) Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias
BR0209992A (pt) Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias
BR0008039A (pt) Combinações de formoterol e um sal de tiotrópio
BR0213397A (pt) Método para suprimento de uma mistura de gases a um paciente, sistema para suprimento de gás a um paciente, usos de halotano, de enflurano, de isoflurano, de sevoflurano e de desflurano no sistema para suprimento, sistema para suprimento de medicamento, e, método para suprimento de medicamento terapêutico
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
BRPI0115910B8 (pt) medicamento compreendendo 5-[(r)-2-(5,6-dietil-indan-2ilamino)-1-hidróxi-etil]-8-hidróxi-1h-quinolin-2-ona e corticóides para o tratamento de doencas inflamatórias ou obstrutivas das vias aéreas
BRPI0514536A (pt) uso de oligossacarìdeos não-digerìveis e sacarìdeo de galactose digerìvel, e, composição adequada para o tratamento e/ou prevenção de infecções do trato respiratório e/ou doença de infecção do trato respiratório
PT1174138E (pt) Utilização de furoato de mometasona para tratar doenças de pulmão e das vias respiratórias
CO5550426A2 (es) Novedoso metodo terapeutico
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
Wilson et al. Efficacy and safety of inhaled carbon monoxide during pulmonary inflammation in mice
WO2007002945A3 (en) P2y6 receptor agonists for treating lung diseases
BR0313503A (pt) Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
BR0214998A (pt) Combinações farmacêuticas de agonistas do receptor da adenosina a-2a e do receptor adrenérgico beta-2
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BR0004813A (pt) Constructos vesiculares marcados para citoproteção e tratamento de infecções por h. pylori
UY27308A1 (es) Un agonista de a2a en combinación con un agente anticolinérgico para el tratamiento de enfermedades obstructivas de las vias aéreas
ECSP034863A (es) Un agonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
Fuchs et al. Intra-alveolar IL-6 levels following burn and inhalation injury
UY27565A1 (es) Combinación farmacéutica.
BR0214776A (pt) Combinação de um inibidor seletivo de pde4 e um agonista do receptor adrenérgico beta-2
HARLING et al. A comparison of thiopentone/isoflurane anaesthesia vs propofol infusion in children having repeat minor haematological procedures
Díaz-Lobato et al. High-flow nasal oxygen is not an oxygen therapy device
UY27307A1 (es) Un inhibidor de pde4 y un agente anticolinérgico en combinación para tratar enfermedades obstructivas de vías respiratorias
ECSP034864A (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A , 5A , 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.